40th week of 2013 patent applcation highlights part 49 |
Patent application number | Title | Published |
20130259764 | PROCESS AND APPARATUS FOR PRODUCING DIESEL FROM A HYDROCARBON STREAM - A process and apparatus are disclosed for hydrotreating a hydrocarbon feed in a hydrotreating unit and hydrocracking a second hydrocarbon stream in a hydrocracking unit. The hydrocracking unit and the hydrotreating unit may share the same recycle gas compressor. A make-up hydrogen stream may also be compressed in the recycle gas compressor. The second hydrocarbon stream may be a diesel stream from the hydrotreating unit. The diesel stream may be a diesel and heavier stream from a bottom of a hydrotreating fractionation column. | 2013-10-03 |
20130259765 | PROCESS AND APPARATUS FOR PRODUCING DIESEL FROM A HYDROCARBON STREAM - A process and apparatus are disclosed for hydrotreating a hydrocarbon feed in a hydrotreating unit and hydrocracking a second hydrocarbon stream in a hydrocracking unit. The hydrocracking unit and the hydrotreating unit may share the same recycle gas compressor. A make-up hydrogen stream may also be compressed in the recycle gas compressor. A hydrocracking separator separates recycle gas and hydrocarbons from the hydrocracking unit to be processed with effluent from the hydrotreating unit. | 2013-10-03 |
20130259766 | PPROCESS AND APPARATUS FOR EFFECIENT RECOVERY OF DICHLOROHYDRINS - A process and apparatus is disclosed for recovering dichlorohydrins from a hydrochlorination reactor effluent stream comprising dichlorohydrins, one or more compounds selected from esters of dichlorohydrins, monochlorohydrins and/or esters thereof, and multihydroxylated-aliphatic hydrocarbon compounds and/or esters thereof, and optionally one or more substances comprising water, chlorinating agents, catalysts and/or esters of catalysts. The reactor effluent stream is distilled to produce a dichlorohydrin-rich vapor phase effluent stream. The dichlorohydrin-rich vapor phase effluent stream is cooled and condensed in two unit operations conducted at two different temperatures and a portion of the liquid phase effluent stream produced by the first unit operation is recycled to the distillation step for reflux. Product streams produced by the process and apparatus are suitable for further processing in a further unit operation, such as dehydrochlorination. Advantages include recovery of high purity dichlorohydrins, more efficient recovery of dichlorohydrins, and reduced capital investment in the recovery equipment. | 2013-10-03 |
20130259767 | WIRE STANDOFFS FOR STACKABLE STRUCTURAL REACTORS - A wire standoff suitable for use in a tubular reactor, such as a reformer, is described. The wire standoff includes a portion or segment positioned between an outer reactor tube and one or more reactor components located within the tube. The reactor components and the outer tube are prevented from coming into directed contact with one another by the positioning of the wire standoff. The wire standoff can be secured to a reactor component at one of its ends or to a washer located between stacked reactor components. Prevention of the reactor components from contact with the outer tube promotes fluid flow through the reactor and can enhance heat transfer and reactor efficiency for carrying out catalytic reactions. | 2013-10-03 |
20130259768 | Micro-Reactor System Assembly - A micro-reactor system assembly comprises a stack of at least n process modules ( | 2013-10-03 |
20130259769 | Catalytic Generation of Metastable Singlet Oxygen - Singlet oxygen metastables can be formed. A catalytic coating is formed on an interior surface of a flow reactor, and an oxygen containing species is flowed into the flow reactor to produce singlet oxygen metastables by a chemical reaction in the presence of the catalytic coating. | 2013-10-03 |
20130259770 | REMOVAL OF LIGHT FLUOROALKANES FROM HYDROCARBON STREAMS - The removal of fluoroalkanes from fluoroalkane-containing hydrocarbon streams, preferably C | 2013-10-03 |
20130259771 | High Bias Gel Tube and Process for Making Tube - An improved fluid collection container, containing a gel separation medium, is provided. The gel is disposed in the tube in a manner and geometry that is readily manufacturable, and which overcomes potential gel movement issues. | 2013-10-03 |
20130259772 | MINIATURE SIEVE APPARATUS AND MANUFACTURING METHOD THEREOF - A miniature sieve apparatus is described and includes a first sieve, a separator and a second sieve from top to bottom. The first and second sieves are formed with at least one first mesh and a plurality of second meshes, respectively. The first and second meshes are misaligned with each other in a vertical direction of the first and second sieves. The miniature sieve apparatus is provided to separate or screen microparticles with different sizes, such as target cells, bio-medical particles, organic or inorganic microparticles. Additionally, the invention also provides a manufacturing method of the miniature sieve apparatus, and the same material is applied to manufacture the sieves and the separators. Thus, the problem caused by the residual thermal stress due to different material can be solved. Therefore, the cost of the miniature sieve apparatus can be lowered as the yield rate thereof is improved. | 2013-10-03 |
20130259773 | RETAINER FOR SAMPLE CARRIERS OF DIFFERENT SHAPES AND SIZES - The disclosure relates to a retainer ( | 2013-10-03 |
20130259774 | COLUMN CONTACT APPARATUS AND METHOD FOR OPERATING THE SAME - The invention is a column contact apparatus for contacting gas with liquid in an upflow in a column container, containing two or more stages of honeycomb structural bodies in the column container in a vertical direction, a space portion formed between the respective stages of the honeycomb structural bodies and a flow-aligning portion as back-flow prevention means provided in the space portion between the respective stages such that the flow-aligning portion is not brought into contact with the honeycomb structural bodies, the flow-aligning portion including a plurality of holes with hole diameters of 0.5 mm to 8 mm. | 2013-10-03 |
20130259775 | Transalkylation Of Heavy Aromatic Hydrocarbon Feedstocks - In a process for producing xylene by transalkylation of a C | 2013-10-03 |
20130259776 | PROCESS FOR SEPARATING AMERICUM FROM OTHER METALLIC ELEMENTS PRESENT IN AN ACIDIC AQUEOUS OR ORGANIC PHASE AND APPLICATIONS THEREOF - A process which allows separation of americium present in an acid aqueous phase or in an organic phase from the other metal elements also found in this phase, by complexation of the americium with a water-soluble ethylenediamine derivative; and a process for selective recovery of americium from an acid aqueous phase containing, in addition to americium, other metal elements, which comprises the application of this separation process. | 2013-10-03 |
20130259777 | TRIBUTYL PHOSPHATE-NITRATE SOLVENT EXTRACTION PROCESS FOR PRODUCING HIGH PURITY NUCLEAR GRADE RARE EARTH METAL OXIDES - A process for the preparation of high purity rare earth metal compounds such as oxides utilizing TBP (tri-butyl phosphate)-nitrate solvent extraction technique adapted to manufacture nuclear grade rare earth metal compounds such as zirconium oxide. The process substantially aids in reducing the specific generation of ammonium nitrate effluent volume thereby increasing its concentration when the effluent comprising ammonium nitrate and ammonium sulphate are utilized for stripping of the rare earth metal compound from the organic solvent in the said process of production of high purity rare earth metal oxide powder. | 2013-10-03 |
20130259778 | METHOD FOR USE IN CONNECTION WITH AN EXHAUST GAS POST-TREATMENT SYSTEM - A method for use with an exhaust gas post-treatment system on an internal combustion engine operated with aft surplus includes reducing nitrous oxides in that an ammonia-separating reducing agent is added to the exhaust gas flow upstream of a catalyst which is charged with a catalyst material for selective catalytic reduction of nitrous oxides. The method further provides that the NH | 2013-10-03 |
20130259779 | CARBON MONOXIDE-SELECTIVE OXIDATION CATALYSTS - Particles of mixed oxides of cerium, zirconium, and copper (CeZrCuO | 2013-10-03 |
20130259780 | METHOD FOR CONTROLLING SOLVENT EMISSIONS FROM A CARBON CAPTURE UNIT - A method and a system for controlling solvent emissions from a carbon capture unit includes passing solvent through a CO | 2013-10-03 |
20130259781 | FLUE GAS TREATMENT SYSTEM WITH AMMONIA SOLVENT FOR CAPTURE OF CARBON DIOXIDE - A system for treating a flue gas from a combustion process comprises an absorber vessel configured to receive an aqueous ammonia solvent stream lean in CO | 2013-10-03 |
20130259782 | METHOD AND DEVICE FOR PRODUCING A FLUID ENRICHED WITH CARBON DIOXIDE FROM A WASTE GAS OF A FERROUS-METALLURGY UNIT - The present invention relates to a process and apparatus for producing a fluid enriched in carbon dioxide starting from a waste gas from a ferrous metallurgy unit. | 2013-10-03 |
20130259783 | LINKER EXCHANGE IN ZEOLITIC IMIDAZOLATE FRAMEWORKS - A method is provided for replacing at least a portion of the organic linker content of a zeolitic imidazolate framework composition. The method comprises exchanging the organic linker with another organic linker. Also provided is a new material, designated as EMM-19, and a method of using EMM-19 to adsorb gases, such as carbon dioxide. | 2013-10-03 |
20130259784 | METHOD AND SYSTEM FOR LOW ENERGY CARBON DIOXIDE REMOVAL - A system and method for removing carbon dioxide from a gas stream. One aspect of the method includes introducing a carbon dioxide containing gas stream to an absorber; contacting the gas stream with an amine-containing solvent; absorbing, with the amine-containing solvent, the carbon dioxide from the gas stream, thereby removing the carbon dioxide from the gas stream; and forming a precipitate with the amine-containing solvent and the carbon dioxide. | 2013-10-03 |
20130259785 | METHOD AND SYSTEM FOR CARBON DIOXIDE REMOVAL - A system and a method is provided for removing carbon dioxide from a gas stream. One aspect of the method includes introducing a carbon dioxide-containing gas stream to an absorber. The gas stream is contacted with an ammonia-containing solvent for absorbing, with the ammonia-containing solvent, the carbon dioxide from the gas stream, thereby removing the carbon dioxide from the gas stream. | 2013-10-03 |
20130259786 | APPARATUS AND METHOD FOR THE REMOVAL OF NITROGEN DIOXIDE FROM A FLUE GAS STREAM - Disclosed herein is an apparatus comprising an absorption chamber; a flue gas stream inlet, the flue gas stream inlet being operative to dispose a flue gas stream in the absorption chamber, wherein the flue gas stream comprises nitrogen dioxide; an absorbing agent inlet, the absorbing agent inlet being operative to dispose an absorbent agent in the absorption chamber, the absorbing agent comprising an absorbing agent compound and a solvent, wherein the absorbing agent is chemically reactive with nitrogen dioxide to absorb nitrogen dioxide from the flue gas stream, forming a reaction product. | 2013-10-03 |
20130259787 | METHOD AND SYSTEM FOR NOx REMOVAL FROM A FLUE GAS - A system for reducing NO | 2013-10-03 |
20130259788 | CONDENSER AND METHOD FOR CLEANING FLUE GASES - An apparatus and method to clean flue gases. As shown in FIG. | 2013-10-03 |
20130259789 | REMOVING SULPHUR OXIDES FROM A FLUID STREAM - A process for removing sulphur oxides from a fluid stream, such as flue gas, that comprises a) providing a non-aqueous absorption liquid containing at least one hydrophobic amine, the non-aqueous absorption liquid being incompletely miscible with water: b) treating the fluid stream in an absorption zone with the non-aqueous absorption liquid to transfer at least part of the sulphur oxides into the non-aqueous absorption liquid and to form a sulphur oxide-hydrophobic amine-complex: c) causing the non-aqueous absorption liquid to be in liquid-liquid contact with an aqueous liquid whereby at least part of the sulphur oxide-hydrophobic amine-complex is hydrolyzed to release the hydrophobic amine and sulphurous hydrolysis products, and at least part of the sulphurous hydrolysis products is transferred into the aqueous liquid; d) separating the aqueous liquid from the non-aqueous absorption liquid. The process mitigates absorbent degradation problems caused by sulphur dioxide and oxygen in flue gas. | 2013-10-03 |
20130259790 | PROCESS FOR PREPARING HIGHER HALOSILANES AND HYDRIDOSILANES - The invention relates to a process for preparing higher halosilanes by disproportionation of lower halosilanes. The invention further relates to a process for preparing higher hydridosilanes from the higher halosilanes prepared by disproportionation. The invention further relates to mixtures containing at least one higher halosilane or at least one higher hydridosilane prepared by the process described. Finally, the invention relates to the use of such a mixture containing at least one higher hydridosilane for producing electronic or optoelectronic component layers or for producing silicon-containing layers. | 2013-10-03 |
20130259791 | PROCESS FOR PREPARING HYDRIDOSILANES - The present invention relates to a process for preparing hydridosilanes from halosilanes, in which a) i) at least one halosilane of the generic formula Si | 2013-10-03 |
20130259792 | EMM19star NOVEL ZEOLITIC IMIDAZOLATE FRAMEWORK MATERIAL, METHODS FOR MAKING SAME, AND USES THEREOF - A method is provided for forming a zeolitic imidazolate framework composition using at least one reactant that is relatively insoluble in the reaction medium. Also provided herein is a material made according to the method, designated either as EMM-19 or as EMM-19*, and a method of using same to adsorb and/or separate gases, such as carbon dioxide. | 2013-10-03 |
20130259793 | Method for Obtaining or Recovering Nitric Acid and Hydrofluoric Acid from Solutions of Stainless Steel Pickling Systems - A method for obtaining or recovering acids, in particular nitric acid and hydrofluoric acid, from solutions and/or metal salts of these acids containing solutions, comprising the steps of: a) spray-drying the solutions at temperatures below the decomposition temperature of the acids, the requisite energy for which is introduced via a gaseous heat-transfer medium, in order to obtain dry metal salts and gaseous acids; b) absorbing the gaseous acids formed in step a); c) separating out the dry metal salts formed in step a); optionally d) roasting the dry metal salts obtained in step a) at temperatures in the range from 400 to 900° C., in order to obtain metal oxides and gaseous acids; and e) absorbing the gaseous acids formed in step d). | 2013-10-03 |
20130259794 | CARBON AND FUEL PRODUCTION FROM ATMOSPHERIC CO2 AND H2O BY ARTIFICIAL PHOTOSYNTHESIS AND METHOD OF OPERATION THEREOF - The present invention relates generally to reduction of atmospheric carbon dioxide and to production of carbon therefrom for further use as, for example, fuel. More specifically, a process of dissolving atmospheric carbon dioxide into a suitable, preferably alkali metal salt flux for electrolysis thereof into carbon and oxygen is also provided. | 2013-10-03 |
20130259795 | LOW TEMPERATURE SINGLE-WALL CARBON NANOTUBE SYNTHESIS - The present disclosure is directed to a method for producing SWCNT from endothermic carbon-containing feedstock, such as, methane gas, using an activated alumina supported Fe:Mo catalyst. The SWCNT growth temperature is less than about 560° C., and the catalyst is activated by exposure to a reducing atmosphere at a temperature greater than about 900° C. | 2013-10-03 |
20130259796 | METHOD AND SYSTEM FOR PRODUCING HIGH-PURITY HYDROGEN CHLORIDE - The present invention provides a method for producing high-purity hydrogen chloride, comprising the steps of: purifying each of crude hydrogen and crude chlorine as raw materials to a purity of 99.999% or higher; reacting an excessive molar amount of the purified hydrogen with the purified chlorine at a temperature ranging from 1,200° C. to 1,400° C. to synthesize hydrogen chloride; converting the hydrogen chloride to a liquid state by compression; and purifying the hydrogen chloride and separating unreacted hydrogen by fractional distillation. The invention also provides a system for carrying out the method. According to the method and system, an environmentally friendly production process can be provided, which can easily produce a large amount of hydrogen chloride having a purity of 3 N (99.9%)-6 N (99.9999%) in a cost-effective manner and enables energy consumption to be significantly reduced. | 2013-10-03 |
20130259797 | METHOD FOR PRODUCING HIGH-PURITY BARIUM CHLORIDE WITH LOW STRONTIUM AND HIGH-PURITY BARIUM CHLORIDE WITH LOW STRONTIUM - High-purity barium chloride (99.60% or more) is produced having low strontium (lower than 10 ppm) by using barium carbonate or a clear barium chloride filtration and hydrochloric acid mixed under agitation at a maintained temperature and pH. The barium chloride is obtained as liquid phase and then crystallized through further processes. | 2013-10-03 |
20130259798 | METHOD OF AND DEVICE FOR OPTIMIZING A HYDROGEN GENERATING SYSTEM - A method of and apparatus for optimizing a hydrogen producing system is provided. The method of optimizing the hydrogen producing system comprises producing hydrogen gas using a hydrogen producing formulation and removing a chemical substance that reduces the hydrogen gas producing efficiency. Further, the hydrogen producing system comprises a hydrogen producing catalyst, a hydrogen generating voltage applied to the hydrogen producing catalyst to generate hydrogen gas, and a catalyst regenerating device to regenerate the hydrogen producing catalyst to a chemical state capable of generating the hydrogen gas when a hydrogen generating voltage is applied. | 2013-10-03 |
20130259799 | HUMAN GM-CSF ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes. | 2013-10-03 |
20130259800 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT - The invention described herein pertains to the use of oxazolidinone antibiotics, alone or in combination, in the treatment of cancer. In particular, the invention pertains to the treatment of malignant gliomas, thyroid cancer or melanoma, or borderline forms of malignant glioma, thyroid cancer or melanoma. | 2013-10-03 |
20130259801 | SERUM AMYLOID P PROTEIN - A method for purifying serum amyloid P protein from fresh unfrozen plasma, includes recalcifying the fresh unfrozen plasma and separation by phenyl-type hydrophobic interaction chromatography. The serum amyloid P protein is also obtainable by the method and the use thereof for therapeutic treatment purposes. A method for determining amyloid deposits in a tissue or organ of a subject is also provided. | 2013-10-03 |
20130259802 | RADIOFLUORINATED COMPOUNDS AND THEIR PREPARATION - The present invention provides a process for [ | 2013-10-03 |
20130259803 | RADIOCONJUGATION METHOD - The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method. | 2013-10-03 |
20130259804 | RADIOTRACER COMPOSITIONS - The present invention relates to improved radiotracer imaging agent compositions, which comprises | 2013-10-03 |
20130259805 | DEVELOPMENT AND SCREENING OF CONTRAST AGENTS FOR IN VIVO IMAGING OF PARKINSON'S DISEASE - The invention provides compounds and a method for imaging aggregated α-synuclein, e.g., Lewy bodies or Lewy neurites, in a tissue or organ. | 2013-10-03 |
20130259806 | DIMERIC MOLECULAR COMPLEXES WITH FREE CYSTEINE RESIDUES AND CONJUGATES THEREOF - The invention relates generally to dimeric molecular complexes comprising two fusion proteins. Each fusion protein comprises a biological effector moiety, a polypeptide spacer sequence, and an IgE CH4 dimerization domain. The dimeric molecular complexes may be conjugated, at a defined site, to other molecules including drug moieties, cytotoxic agents, labels (such as detectable labels), or biocompatible polymers. | 2013-10-03 |
20130259807 | CELL CULTURE SCREEN FOR AGENTS THAT CONTROL ADIPOGENESIS AND MYOFIBROBLAST DIFFERENTIATION - Methods are provided for the rapid and robust screening test agents for adipogenic activity. Agents testing positive in the assays are good candidate agents for wrinkle reduction, normalizing skin appearance after reconstructive or cosmetic surgery, e.g., grafted tissue on burn victims, normalizing skin appearance during and after wound healing, and the like. In certain embodiments the methods involve providing mammalian test cells with adipogenic potential wherein said cells are primed for, but withheld from differentiation into adipocytes; contacting the cells with the test agent(s); and screening said test cells for an adipocyte phenotype wherein the presence of a feature characteristic of an adipocyte is an indicator that said test agent is adipogenic. | 2013-10-03 |
20130259808 | MULTIFUNCTIONAL NANOPARTICLES - Multifunctional nanoparticles can include two or more different populations of nanocrystals that impart a combination of properties arising from the constituent populations in a single, multifunctional nanoparticle. | 2013-10-03 |
20130259809 | USE OF POLYSACCHARIDES FROM RADIX ISATIDIS IN MANUFACTURE OF MEDICAMENTS AGAINST INFLUENZA VIRUS - A process of using | 2013-10-03 |
20130259810 | Stannous Salt and Sodium Tripolyphosphate Oral Care Compositions and Methods - Oral care compositions containing a stannous salt and sodium tripolyphosphate are provided where stannous tripolyphosphate ionic intermediates comprise less than about 1% of the compositions Tetrasodium pyrophosphate, a methylvinyl ether-maleic anhydride copolymer and/or a silica oral polishing agent may be added for further efficacy. In a single phase blend, the oral care composition may be effectively limited to comprise less than about 10% water. In a dual-phase blend, a mixture having the stannous salt in a first phase and the sodium tripolyphosphate in a second phase may be generated from a dual chamber storage tube (with each phase provided from a separate chamber) immediately prior to dental care usage. | 2013-10-03 |
20130259811 | Tooth Whitening Dental Tray and Method of Use - A dental tray with a hydrophobic tooth whitening formulation where the tooth whitening formulation is substantially non-water soluble, and a method of using this dental tray to whiten the teeth. The tooth whitening formulation is primarily comprised of a hydrophobic polymer and a peroxide or a peroxide yielding compound. Preferably the hydrophobic polymer is the condensation product of a silicone resin and an organosiloxane. The dental tray is formed to encompass the front and the rear surfaces of the teeth. The dental tray is comprised of a thermoplastic or thermoset polymer. The teeth whitening formulation is placed into the dental tray and the tray placed against the teeth to be whitened. This is for a sufficient period of time to at least partially whiten teeth. This can be a period of time from about 0.5 hour to 2 hours or more. The substantially non-aqueous tooth whitening formulation is effective over a longer period of time since it is not significantly diluted or removed from the dental tray during the treatment time. | 2013-10-03 |
20130259812 | CATIONIC POLYMER LATEXES AND USES - Described are novel polymers and home and personal care compositions incorporating said polymers. | 2013-10-03 |
20130259813 | HIGH PROTECTION UVA/UVB COMPOSITION ITS PREPARATION PROCESS AND TOPICAL COSMETIC COMPOSITION - The present invention relates to a high protection UVA/UVB composition comprising (a) about 0.5 to about 7.5% by weight of phenylbenzimidazole sulfonic acid; (b) about 0.1 to about 2.5% by weight of triethanolamine; (c) about 1 to about 11% by weight of an UVA chemical filter; (d) about 10 to about 50% by weight of an additional chemical filter; and (e) about 40 to about 70% by weight of an alcoholic carrier, wherein all percentages are based on the total weight of the high protection UVA/UVB composition and the water is not present. This composition have a high SPF and an appropriated PPD having a fluid and transparent aspect and having pleasant sensory characteristics. Furthermore, the present invention relates to a Process for preparing said high protection UVA/UVB composition comprising the following steps: (i) solubilize triethanolamine in alcoholic carrier, and (ii) when stirring, add phenylbenzimidazole sulfonic acid to the mixture obtained in step (i); (iii) in parallel, heat the additional chemical filters at a temperature ranging from about 50 to about 70° C., preferably about 60° C.; (iv) remove from the heating the mixture obtained in step (iii) and when it is at a temperature ranging from about 30 to about 50° C., preferably about 40° C., add it to the mixture obtained in step (ii); and (v) stir to obtain the final composition. | 2013-10-03 |
20130259814 | LONG WEAR COSMETIC COMPOSITIONS CONTAINING POSS THERMOPLASTIC ELASTOMERS - Disclosed are cosmetic compositions and methods of making up keratinous tissue in a way that preserves long-wear but also greater comfort, reduced tackiness and enriched color, and which entail use of polyhedral oligomeric silsequioxanes (POSS)-grafted polyolefins. | 2013-10-03 |
20130259815 | METHODS OF LIGHTENING THE SKIN - Provided are methods of lightening skin by applying certain aromatic compounds or botanical extracts containing such compounds to the skin. | 2013-10-03 |
20130259816 | Method of Formulating a Skin-Lightening Composition - A method of formulating a skin-lightening composition by identifying actives with a data architecture and incorporating the actives into a skin care composition. The data architecture can be used to identify connections between perturbagens and genes associated with skin tone. A gene expression profile for a control human cell is compared to the gene expression profile a cell exposed to perturbagen to identify the genes which are differentially expressed. The differentially expressed genes are analyzed and arranged into an ordered list of identifiers, which along with other instances create a data architecture. | 2013-10-03 |
20130259817 | Hair Conditioning Composition Comprising Mono-Alkyl Amine Cationic Surfactant System, Deposition Polymer, and Silicone - Disclosed is a hair conditioning composition comprising: a mono-alkyl amine cationic surfactant; a di-alkyl quaternized ammonium salt cationic surfactant; a high melting point fatty compound; a deposition polymer having specific monomers; a silicone compound; and an aqueous carrier. The composition of the present invention provides improved deposition of cationic surfactant, fatty compounds, and/or silicone compounds, especially silicone compounds on damaged hair. | 2013-10-03 |
20130259818 | METHYL ETHYL HYDROXYETHYL CELLULOSE FOR PERSONAL CARE APPLICATIONS - A thickening system for personal care formulations including methyl ethyl hydroxyethyl cellulose provides efficient thickening power in applications areas such as shampoo and styling gels. In addition to providing thickening, the methyl ethyl hydroxyethyl cellulose derived polymers also provide foam stability to shampoos and improved high humidity curl retention to hair gel compositions. | 2013-10-03 |
20130259819 | Hair Conditioning Composition Comprising Higher Percent of Cationic Surfactant and Deposition Polymer - Disclosed is a hair conditioning composition comprising: a cationic surfactant; a high melting point fatty compound; a deposition polymer having specific monomers; and an aqueous carrier; wherein the mole % of the cationic surfactant to a sum of the cationic surfactant and the high melting point fatty compound is from about 20% to about 60%. The composition of the present invention provides improved friction reduction on wet hair, while providing improved deposition of cationic surfactant, fatty compounds, and/or silicone compounds. | 2013-10-03 |
20130259820 | HAIR CONDITIONING COMPOSITIONS COMPRISING LOW VISCOSITY SILICONE POLYMERS - Embodiments of a hair conditioning composition comprise a silicone polymer comprising one or more quaternary groups, at least one silicone block comprising greater than 200 siloxane units, at least one polyalkylene oxide structural unit, and at least one terminal ester group, the silicone polymer having a viscosity of up to 100,000 mPa·s, and wherein the a hair conditioning composition comprises a gel matrix comprising a cationic surfactant, a high melting point fatty compound, and an aqueous carrier. | 2013-10-03 |
20130259821 | FORMULATION COMPRISING POLYSILOXANES HAVING NITROGEN-CONTAINING GROUPS - The invention relates to the use of multiamino-functional polysiloxanes in formulations and to the formulations comprising these polysiloxanes. | 2013-10-03 |
20130259822 | MALODOR NEUTRALIZING COMPOSITIONS CONTAINING ACIDS AND ALICYCLIC KETONES - This disclosure relates to a malodor neutralizing composition containing (1) a cyclohexanone substituted with C | 2013-10-03 |
20130259823 | HYDROGEN PEROXIDE-BASED SKIN DISINFECTANT - An aqueous skin disinfecting solution has a pH of from about 2 to about 6, and consists of at least (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w; (b) at least one surfactant chosen from alkyl betaines, alkyl amidopropyl betaines, alkyl amidopropyl betaine amides, alkylsulfobetaines, alkyl amphocarboxylates and amine oxides in a concentration of from about 0.01 to about 15% w/w; (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4% w/w; (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w; (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w; and (f) an effective amount of at least one solvent. The invention can be provided in concentrated or dried powdered form. | 2013-10-03 |
20130259824 | Treatment for Ischemic Stroke - Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent. | 2013-10-03 |
20130259825 | Method for Enhancing Umbilical Cord Blood Engraftment - A method for enhancing bone marrow cells, peripheral blood, and umbilical cord blood engraftment is disclosed wherein at least one of a granulocyte colony stimulating factor and a granulocyte macrophage colony stimulating factor, and optionally romiplostim, and optionally an erythropoiesis-stimulating agent, are added thereto for enhancing the engraftment of CD44 cells within the bone marrow cells, peripheral blood, and umbilical cord blood. Also provided is a method for enhancing a stem cell infusion by activating an up-regulation of a AF1q/CD44 signaling pathway. A stem cell product is disclosed having treated stem cells conditioned for activating an up-regulation of a AF1q/CD44 signaling pathway. | 2013-10-03 |
20130259826 | COMPOSITIONS, METHODS AND USES FOR STIMULATING IMMUNE RESPONSES - Embodiments herein report compositions, methods and uses for inducing an innate immune response in a subject. Embodiments herein also generally report compositions, methods and uses for bacterial-derived peptides to induce an innate immune response in a subject having a bacterial or viral disorder and/or cancer. In certain embodiments, compositions herein concern derivatives of p60 protein of | 2013-10-03 |
20130259827 | USE OF INTERLEUKIN-15 TO TREAT CARDIOVASCULAR DISEASES - The present disclosure relates generally to the field of cardiovascular diseases. In particular, the present disclosure relates to methods and compositions for treating cardiovascular diseases by administration of a cytokine alone, or in conjunction with other therapeutic agents. | 2013-10-03 |
20130259828 | USES OF IL-12 AND THE IL-12 RECEPTOR POSITIVE CELL IN TISSUE REPAIR AND REGENERATION - The present application relates to stem cells isolated from various sources within the body of a patient or of a healthy donor and identified by the presence of the interleukin 12 (IL-12) receptor. The present application also provides methods for making and for using the stem cells. | 2013-10-03 |
20130259829 | CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE FUNCTION - The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, allergic disease transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS. | 2013-10-03 |
20130259830 | CRTH2 MODULATORS - Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by Formula I: | 2013-10-03 |
20130259831 | 3,5-Disubstituted and 3,5,7-Trisubstituted-3H-Oxazolo and 3H-Thiazolo[4,5-d]pyrimidin-2-one Compounds and Prodrugs Thereof - The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs. | 2013-10-03 |
20130259832 | Combinations of Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations. | 2013-10-03 |
20130259833 | AAV-Mediated Subcellular Targeting of Heterologous Rhodopsins in Retinal Ganglion Cells - Microbial type rhodopsins, such as the light-gated cation-selective membrane channel, channelrhodopsin-2 (Chop2/ChR2) or the ion pump halorhodopsin (HaloR) are expressed in retinal ganglion cells upon transduction using recombinant AAV vectors. Selective targeting of these transgenes for expression in discrete subcellular regions or sites is achieved by including a sorting motif in the vector that can target either the central area or surround (off-center) area of these cells. Nucleic acid molecules comprising nucleotide sequences encoding such rhodopsins and sorting motifs and their use in methods of differential expression of the transgene are disclosed. These compositions and methods provide significant improvements for restoring visual perception and various aspects of vision, particular in patients with retinal disease. | 2013-10-03 |
20130259834 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC PEPTIDES - Methods and compositions for targeted delivery of biotherapeutics are provided. The compositions comprise bile-sensitive | 2013-10-03 |
20130259835 | BIFIDOBACTERIUM ADOLESCENTIS SPM0212 HAVING ANTIVIRAL ACTIVITY FOR HEPATITIS B VIRUS, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING HEPATITIS B COMPRISING THEREOF - The present invention relates to a | 2013-10-03 |
20130259836 | MATURE HEPATOCYTE CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS, A GENERATING METHOD THEREOF, AND USE THEREOF FOR TREATMENT OF LIVER DISEASES - The present invention describes an efficient and rapid protocol to generate hepatocyte cells from human induced pluripotent stem cells (iPSCs). According to the method, the iPS cells can be differentiated into functional hepatocyte cells in a short time course (less than 15-20 days). The iPSC-derived hepatocyte cells of the invention have a similar gene expression profile to mature hepatocytes. Moreover, the iPSC-derived hepatocyte cells is proved to rescue lethal fulminant hepatic failure in a non-obese diabetic severe combined immunodeficient mouse model. The rapid and efficient differentiation protocol for generation of iPSC-derived hepatocyte cells may offer an alternative option for treatment of liver diseases. | 2013-10-03 |
20130259837 | Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 2013-10-03 |
20130259838 | CULTURED CARTILAGE TISSUE MATERIAL - Provided is a cultured cartilage tissue material which enables formation of cartilage tissue being substantially the same as the cartilage tissue actually in the living body, and which is large in volume. The cultured cartilage tissue material is to be used for cartilage regeneration and comprises chondrocytes, and is a mixed body of chondrocytes in a concentration of 1×10 | 2013-10-03 |
20130259839 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF TISSUE OF ORIGIN OF TUMOR SAMPLES - The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy. | 2013-10-03 |
20130259840 | PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD - Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC−/− progenitor cells, and is useful to grow and repair human tissues including bone. | 2013-10-03 |
20130259841 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors - Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 | 2013-10-03 |
20130259842 | STABLE REPROGRAMMED CELLS - The present invention relates to a stable pluripotent reprogrammed cells, and compositions and methods of isolation and uses thereof, wherein the stable pluripotent reprogrammed cells is derived from a somatic cell and has undergone incomplete remodeling of the epigenome. In some embodiments, the stable reprogrammed cell is a human stable reprogrammed cell. In some embodiments, the stable reprogrammed cell has a statistically significant lower level of expression of one or any combination of Nanog, Dnmt3b, Lefty2 as compared to an induced pluripotent stem cell. In some embodiments, the stable reprogrammed cell has a statistically significant higher level of expression of one or any combination of Tdgf1, Tert or endogenous Sox2 as compared to a somatic cell from which it was derived. In some embodiments, the stable reprogrammed cell has a statistically significant faster rate of doubling as compared to an induced pluripotent stem cell (iPSC) or an embryonic stem (ES) cell. Other aspects of the invention relate to compositions comprising the reprogrammed cell, method of isolation and method of use. | 2013-10-03 |
20130259843 | SKELETAL MUSCLE REGENERATION USING MESENCHYMAL SYSTEM CELLS - The present invention relates to a therapeutic substance and/or medicament and methods relating to the use of said substance and/or medicament for skeletal muscle regeneration using mesenchymal stem cells (MSCs) which can be applied directly or shortly after muscle damage or injury. | 2013-10-03 |
20130259844 | Fermented Foodstuff - A fermented foodstuff composition for human consumption is provided, the foodstuff composition being prepared by the fermentation of a foodstuff substrate with a lactic acid producing bacteria, the lactic acid bacteria being characterised by:
| 2013-10-03 |
20130259845 | TREATMENT OF PREMATURE BIRTH COMPLICATIONS - The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants. | 2013-10-03 |
20130259846 | Method for Mosquito Control - A formulation and method for insect control is provided in the form of insecticide carrying insects which can be introduced in a population to thereby control the insect population. The formulation may include artificially generated adult insect carriers of a larvicide in which the larvicide has minimal impact on the adult insect and which larvicide affects juvenile survival or interferes with metamorphosis of juvenile insects to adulthood. The insects may be either male or female and may include mosquitoes. | 2013-10-03 |
20130259847 | INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF - Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building | 2013-10-03 |
20130259848 | ENZYME COMBINATIONS TO REDUCE BRAIN TISSUE SWELLING - Tissue fixed charge density (FCD) is identified as another potential therapeutic target for reducing brain tissue swelling. Reduction of the FCD could reduce the thermodynamic force driving water entry into the brain. The present invention discloses chondroitinase ABC (ChABC) reduces tissue FCD and reduces tissue swelling, indicating that it may be an effective treatment to reduce edema and control intracranial pressure. | 2013-10-03 |
20130259849 | Enhanced Antimicrobial Lytic Activity of a Chimeric Ply187 Endolysin - Peptidoglycan hydrolases are an effective new source of antimicrobials. A chimeric fusion protein of the Ply187 endopeptidase domain and LysK SH3b cell wall binding domain is a potent agent against | 2013-10-03 |
20130259850 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. | 2013-10-03 |
20130259851 | USE OF PROKARYOTIC SPHINGOSINE-1-PHOSPHATE LYASES AND OF SPHINGOSINE-1-PHOSPHATE LYASES LACKING A TRANSMEMBRANE DOMAIN FOR TREATING HYPERPROLIFERATIVE AND OTHER DISEASES - The present invention relates to the use of prokaryotic sphingosine-1-phosphate lyases (S1PL) and S1PLs that lack a transmembrane domain or of a nucleic acid encoding such an S1PL in the prevention or treatment of a disease condition associated with elevated levels of sphingosine-1-phosphate (S1P), and for which S1P elevation is directly or indirectly causative. In addition, the invention relates to a new product in the form of S1PL lacking the N-terminal loop domain. | 2013-10-03 |
20130259852 | LYSOZYME GEL FORMULATIONS - The present invention relates to formulations of gelled lysozyme achieved by the addition of water to a lysozyme suspension in a solvent, such as an alcohol, with retention of enzymatic activity. It was surprisingly discovered that lysozyme itself is a gelling substance (self-gel) and, therefore, it can be advantageously formulated into topical compositions without the addition of other gelling substances such as cellulose, starch or other polysaccharides. The activity of the lysozyme is enhanced as compared to other formulations of comprising lysozyme. The formulations contained in the present invention are useful in methods in the fields of therapeutics, disinfectants, sanitizers, personal hygiene, and cosmetics for human and veterinary use. | 2013-10-03 |
20130259853 | Treatment of Acute Ischemic Stroke or Intracranial Bleeding with tPA and Carbamylated Erythropoietin - The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of carbamylated erythropoietin. | 2013-10-03 |
20130259854 | METHODS AND COMPOSITIONS FOR REDUCING THE INCIDENCE OF POST-SURGICAL ADHESIONS - The disclosure relates to a method of reducing the incidence of post-surgical adhesions in a subject undergoing surgery. More specifically, the method relates to reducing the incidence of post-surgical adhesions with the topically administration of activated protein C (APC) to the internal organs and tissues exposed and/or manipulated during surgery. | 2013-10-03 |
20130259855 | COMPOSITION COMPRISING FERMENTED TEA EXTRACTS FOR REDUCING LIPID LEVEL - The present invention relates to a composition for reducing in-vivo lipid level, inhibiting lipoclasis and promoting discharge of a lipid, wherein the composition comprises, as active ingredients, fermented tea extracts obtained by inoculating strains to tea, wherein the strains are derive from fermented Korean traditional condiment. | 2013-10-03 |
20130259856 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND DIMETHYL FUMARATE - This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 2013-10-03 |
20130259857 | METHODS FOR INHIBITING FASCIN - The invention relates to compositions and methods useful for inhibiting fascin. These compositions and methods can be used to inhibit fascin-related diseases. For example, according to the invention inhibition of fascin inhibits metastasis of tumor cells in mammals. | 2013-10-03 |
20130259858 | Signature for Predicting Clinical Outcome in Human HER2+ Breast Cancer - A method of predicting outcome in a subject with for example Her2+ (ERα | 2013-10-03 |
20130259859 | ANG2-BINDING MOLECULES - Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same. | 2013-10-03 |
20130259860 | Humanized Antibodies To LIV-1 And Use Of Same To Treat Cancer - The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1. | 2013-10-03 |
20130259861 | TREATMENT OF AUTOIMMUNE DISORDERS - This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof. | 2013-10-03 |
20130259862 | ANTIBODY-MEDIATED TRANSDUCTION OF HEAT SHOCK PROTEINS INTO LIVING CELLS - The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus. | 2013-10-03 |
20130259863 | TFPI INHIBITORS AND METHODS OF USE - The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound. | 2013-10-03 |